Using genetic testing to improve emergency care
Trial of Precision Medicine in Emergency Departments
This study is testing if using genetic testing in emergency rooms can help doctors choose better treatments and reduce the number of times patients need to come back.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1200 (estimated) |
| Ages | 40 Years and up |
| Sex | All |
| Sponsor | University of Florida Academic / other |
| Locations | 3 sites (Gainesville, Florida and 2 other locations) |
| Trial ID | NCT06448091 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the feasibility of implementing preemptive pharmacogenetic testing in emergency departments to improve patient outcomes. It will assess whether this testing, combined with decision support, can reduce return visits to the emergency department and hospitalizations. The trial will be conducted in several UF Health emergency departments and will involve a randomized, controlled approach to measure both effectiveness and implementation outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 40 and older who have had multiple prior emergency department visits and are receiving a new prescription for a pharmacogenetic medication.
Not a fit: Patients with prior pharmacogenetic test results or severe liver or renal conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to more personalized medication management in emergency settings, potentially reducing complications and hospital readmissions.
How similar studies have performed: Other studies have shown promise in using pharmacogenetic testing to improve medication management, indicating that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults 40 years or older presenting to a participating ED 2. Receipt of a new order/prescription for a selected PGx medication (Appendix 1), with a duration greater than 7 days, during the current ED visit or within 30 days prior. 3. Documentation of at least 2 prior ED or urgent care visits within the past 12 months Exclusion Criteria: 1. Prior clinical pharmacogenetic test results within the EHR for genes relevant for this study (Appendix 1). 2. History of hepatic or renal transplant 3. History of severe liver disease (stage Child-Pugh C) or renal disease eGFR \<15 ml/min. 4. Any medical condition that would prohibit the ability to complete the study 5. Prisoners, wards of the state, or patients being held under the Baker Act or Marchman Act 6. Life expectancy less than 6 months
Where this trial is running
Gainesville, Florida and 2 other locations
- UF Health Emergency Department — Gainesville, Florida, United States (Not_yet_recruiting)
- UF Health Jacksonville Downtown Emergency Department — Jacksonville, Florida, United States (Recruiting)
- UF Health Jacksonville North Emergency Department — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Julio D Duarte, Pharm.D., Ph.D. — University of Florida
- Study coordinator: Erica N Elwood, MHA
- Email: erica.elwood@cop.ufl.edu
- Phone: 3522736007
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.